JP2025525308A - 新規の脂質ナノ粒子組成物およびその使用 - Google Patents
新規の脂質ナノ粒子組成物およびその使用Info
- Publication number
- JP2025525308A JP2025525308A JP2024571035A JP2024571035A JP2025525308A JP 2025525308 A JP2025525308 A JP 2025525308A JP 2024571035 A JP2024571035 A JP 2024571035A JP 2024571035 A JP2024571035 A JP 2024571035A JP 2025525308 A JP2025525308 A JP 2025525308A
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- cells
- composition
- lipids
- ganglioside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263356557P | 2022-06-29 | 2022-06-29 | |
| US63/356,557 | 2022-06-29 | ||
| PCT/US2023/026541 WO2024006414A1 (en) | 2022-06-29 | 2023-06-29 | Have been novel lipid nanoparticle compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025525308A true JP2025525308A (ja) | 2025-08-05 |
| JP2025525308A5 JP2025525308A5 (OSRAM) | 2026-04-17 |
Family
ID=89381439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024571035A Pending JP2025525308A (ja) | 2022-06-29 | 2023-06-29 | 新規の脂質ナノ粒子組成物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12303569B2 (OSRAM) |
| EP (1) | EP4547224A1 (OSRAM) |
| JP (1) | JP2025525308A (OSRAM) |
| CN (1) | CN119403544A (OSRAM) |
| AU (1) | AU2023297939A1 (OSRAM) |
| WO (1) | WO2024006414A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120948302A (zh) * | 2024-05-13 | 2025-11-14 | 国立医药品食品卫生研究所 | 使用离心场流分级检测颗粒的方法 |
| WO2025250539A1 (en) * | 2024-05-29 | 2025-12-04 | Cytodigm, Inc. | Pharmaceutical composition comprising sialic acid for treating diseases related to the lung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150291969A1 (en) * | 2014-01-30 | 2015-10-15 | Chromatin, Inc. | Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same |
| AU2020301161B2 (en) * | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| CN116568331A (zh) * | 2020-10-05 | 2023-08-08 | 希托迪格姆公司 | Siglec-结合剂的药物组合物 |
-
2023
- 2023-06-29 JP JP2024571035A patent/JP2025525308A/ja active Pending
- 2023-06-29 AU AU2023297939A patent/AU2023297939A1/en active Pending
- 2023-06-29 CN CN202380047304.0A patent/CN119403544A/zh active Pending
- 2023-06-29 EP EP23832332.3A patent/EP4547224A1/en active Pending
- 2023-06-29 WO PCT/US2023/026541 patent/WO2024006414A1/en not_active Ceased
-
2024
- 2024-09-10 US US18/829,557 patent/US12303569B2/en active Active
- 2024-12-10 US US18/975,168 patent/US20250099394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023297939A1 (en) | 2024-11-28 |
| WO2024006414A1 (en) | 2024-01-04 |
| EP4547224A1 (en) | 2025-05-07 |
| US12303569B2 (en) | 2025-05-20 |
| WO2024006414A8 (en) | 2025-02-27 |
| CN119403544A (zh) | 2025-02-07 |
| US20250001003A1 (en) | 2025-01-02 |
| US20250099394A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220125929A1 (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor | |
| CN101291653B (zh) | 脂质包封的干扰rna | |
| US12303569B2 (en) | Lipid nanoparticle compositions and uses thereof | |
| CN1882693B (zh) | 聚乙二醇修饰的脂质化合物及其应用 | |
| AU2022434120B2 (en) | Cationic lipid compound, composition containing same and use thereof | |
| JP5592897B2 (ja) | アニオン性薬物含有薬剤学的組成物及びその製造方法 | |
| US20060051405A1 (en) | Compositions for the delivery of therapeutic agents and uses thereof | |
| KR20230138496A (ko) | 핵산 전달에 적합한 지질 | |
| WO2016121942A1 (ja) | カチオン性脂質 | |
| CN1981044A (zh) | 包封干扰rna的脂质 | |
| WO2025021083A1 (en) | Lipid nanoparticle compositions for localized treatment of skin diseases | |
| CA3247039A1 (en) | LIPID NANOPARTICLES FOR THE ADMINISTRATION OF A NUCLEIC ACID TO SPLENIC TISSUE AND RELATED METHOD OF ADMINISTRATION | |
| KR20240083166A (ko) | 폐를 표적장기로 하는 생분해성 지질나노입자 약물 전달 제형 및 이의 활용 | |
| WO2000025748A1 (en) | Liposomes | |
| CN114685784A (zh) | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 | |
| US20260000627A1 (en) | Novel lipid nanoparticle compositions and uses thereof | |
| CN117534585B (zh) | 一种可电离阳离子脂质化合物及其制备方法与应用 | |
| WO2024121167A1 (en) | Compounds and compositions for delivery of agents to cells | |
| CN114940756A (zh) | 一种聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 | |
| WO2026036007A1 (en) | Novel lipid nanoparticle compositions and uses thereof for treating diseases in bone marrow | |
| EP4563142A1 (en) | Lipid nanoparticle and pharmaceutical composition | |
| WO2024203660A1 (ja) | 核酸内封脂質ナノ粒子の製造方法 | |
| CN121796628A (zh) | 一种靶向脂质纳米颗粒及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241223 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260408 |